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intake or plasma levels of lutein in our study, although this could
be undertaken.
A number of epidemiologic studies have now demonstrated an
association between dietary intake or plasma levels of antioxidant
vitamins and the risk of atherosclerotic vascular disease. However,
large-scale randomized trials to test further for a causal relationship
between antioxidant intake and ischemic heart disease have pro-
vided conflicting results (2). Although there is plausible biological
evidence to suggest antioxidants may prevent the early stages of
atherogenesis, it is unknown as to whether they alter the later
processes that produce clinical events. To determine the role of
antioxidant vitamins in atherosclerosis, it may be more appropriate
to examine the relationship between dietary intake or plasma levels
of these vitamins and measures of early atherosclerosis rather than
clinical cardiovascular events (3).
Although we remain very interested in investigating antioxidant
defenses against lipid peroxidation and novel risk factors for
atherosclerosis, we would support the concept that this essential
ongoing research should not distract us from efforts to implement
more proven preventive strategies (4).
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Controlling the Effectiveness of Digoxin
In a recent issue of the Journal, Adams, et al. (1) correctly stated
that: “Patients taking digoxin did significantly better than those
not taking the drug, but the serum concentration did not correlate
with outcome.” Nevertheless, they concluded: “These results sup-
port the possibility that a lower therapeutic goal for serum digoxin
concentration is warranted in patients with heart failure.”
This conclusion is flawed because in individual patients the
concentration of digoxin in the serum does not accurately represent
the amount of digoxin in the tissues where it works. The digoxin
in the serum is only a tiny fraction of the total amount of digoxin
in the body. The total amount of digoxin in the body is easy to
calculate from the doses administered, and it does correlate with
outcome (2–4). Guiding dosage this way allowed high doses of
digoxin (15 to 19 g/kg of lean body weight) to be given to
patients after cardiac operations, and the patients recovered rapidly
(5,6).
Because serum digoxin concentrations poorly guide dosage and
results, contradictions between serum levels and results have been
seen by many doctors. Low serum concentrations of digoxin
appeared in patients who received therapeutic benefits. In contrast,
high serum concentrations of 2.5 ng/ml have been seen in patients
who had no signs or symptoms of toxicity.
Dr. Jelliffe published a method for calculating the milligrams of
digoxin needed to produce a specific peak total body load of
digoxin and to engender a desired therapeutic result (2–4). A safe,
effective amount of peak total body digoxin to treat heart failure is
8 to 10 g/kg of lean body weight. This program is used at the
University of Southern California/Los Angeles County Medical
Center and at several other hospitals.
Studying the effects of digoxin requires knowing the total
amount of digoxin in the body, which controls the amount of
digoxin in the tissues where digoxin works.
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REPLY
We appreciate Dr. Krohn’s interest and comments concerning our
analysis. We believe our conclusions as stated in the study are
correct. While it is true that the serum digoxin concentration
(SDC) is significantly higher than the tissue concentration during
the distributive phase of digoxin dosing (6 to 12 h), both the SDC
and the amount of drug in the body decline in parallel and are
directly related 12 to 24 h post-dose (1). This is the rationale for
the recommendation to always draw the SDC as a trough
concentration—that is, 24 h after the dose (2). This was mandated
in both the PROVED and RADIANCE protocols.
We agree with Dr. Krohn’s statement that total body stores of
digoxin are easy to calculate. Unfortunately, we are unable to do
this for each individual patient in these studies. However, the
dosing guidelines cited by Dr. Krohn are incorporated into the
dosing table that is currently included in the Lanoxin package
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insert (2). A similar strategy was used in the PROVED, RADI-
ANCE, and DIG studies, which produced mean SDCs in the
range of 0.9 to 1.2 ng/ml. We also agree that the current
therapeutic range for digoxin (0.8 to 2.0 ng/ml) is poorly defined
and is based primarily on toxicity—not efficacy. As Dr. Krohn
states, some patients may have high concentrations (2.0 ng/ml)
without evidence of toxicity, whereas others may have relatively
low concentrations and demonstrate efficacy, a point we are
attempting to make with our study. However, it is clear that, in
general, the higher the concentration, the greater the risk for
toxicity. Our analysis, within the limitations indicated, finds no
evidence for a relationship between serum concentration and
efficacy. Patients who continued digoxin, including those with a
low SDC, did better than those who had it withdrawn. Because
lower SDCs appear to be effective, toxicity can be minimized with
a low dose of digoxin while preserving clinical benefit.
Finally, Dr. Krohn notes the high doses of digoxin used for the
acute management of supraventricular arrhythmias postoperatively,
whereas our analysis focuses on the outpatient management of
patients with chronic heart failure. We would suggest that, for a
number of reasons (age, left ventricular function, renal function,
etc.), these may be two totally different patient populations. Their
handling of digoxin, requirement of higher SDC, and ability to
tolerate a higher SDC may differ as well. Perhaps the most
important point is that the SDC should not serve as the sole
marker for efficacy or toxicity but should be taken into consider-
ation along with the patient’s clinical information. The dose and
SDC should always be individualized for any given patient.
Optimal dosing remains a vital but relatively poorly studied
aspect of cardiovascular therapeutics. We believe our work provides
useful data concerning dosing of digoxin, a medication that
remains among the most commonly prescribed worldwide for heart
failure.
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Long-Term Outcome in Patients
With Apical Hypertrophic Cardiomyopathy
We read with interest the study by Eriksson et al. (1), which
described the long-term outcome in patients with apical hypertro-
phic cardiomyopathy (A-HCM). The characteristic hallmarks of
A-HCM as originally described (2) included the presence of giant
negative T waves and a spade-like configuration at end-diastole on
left ventriculography. Only 47% of their patients had giant
negative T waves at baseline. Other forms of so-called A-HCM
such as that described by Maron et al. (3) relate to cases with apical
distribution of septal hypertrophy with mid-ventricular constric-
tion rather than the typical concentric apical hypertrophy of the
Japanese form. They offer a very different clinical presentation,
electrocardiogram, morphology, and prognosis (4,5).
As described initially in Japan, A-HCM is also found in
non-Japanese patients (4–6) provided one adheres to the original
criteria (2). In a longitudinal study fulfilling the exact “Japanese”
criteria of A-HCM, patients were followed for 5 to 20 years (6).
Sustained ventricular tachycardia in 18% and atrial fibrillation in
another 18% of patients appeared as a very late complication. The
T-wave negativity was reduced in 36% and loss of R-wave voltage
was found in 27% of cases. Thus, patients may lose some of their
electrocardiographic diagnostic characteristics and may develop
life-threatening arrhythmias (6,7). One such patient with normal
coronary arteries who had an automatic internal pacemaker defi-
brillator implanted for recurrent ventricular tachycardia developed
an apical aneurysm with clot and has since died of severe
pulmonary edema. Moreover, knowledge of the possibility of late
aneurysmatic formation in A-HCM in the absence of coronary
artery disease is mandatory to avoid the misdiagnosis of congenital
defects in the form of Cantrell’s syndrome (8,9).
In our study, reduction in T-wave negativity and R-wave
voltage was not associated with myocardial infarction (MI) as
reported by the investigators (1). In what percentage of their
patients were these electrocardiographic changes associated with
MI?
Lacking long-term studies and owing to the rarity of true
A-HCM outside Japan, the prognosis has generally been consid-
ered benign based primarily on Japanese observations. However,
considering recent Japanese experience (7) and our own (6) in
addition to that of Eriksson et al. (1), in whose patients one-third
did develop “unfavorable clinical events and potentially life-
threatening complications, such as myocardial infarction, arrhyth-
mia and stroke,” all suggest that a complacent approach in this
entity is unsafe. Close long-term follow-up is essential to reveal
and manage in time potentially fatal complications, particularly in
the elderly. Additional studies are needed to investigate further the
genetic basis of A-HCM and to define risk-stratification strate-
gies. In our opinion, A-HCM can no longer be viewed as a benign
entity neither inside nor outside Japan.
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